Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease

被引:34
|
作者
Valgimigli, Marco [1 ,2 ]
Aboyans, Victor [3 ,4 ]
Angiolillo, Dominick [5 ]
Atar, Dan [6 ,7 ]
Capodanno, Davide [8 ]
Halvorsen, Sigrun [9 ,10 ]
James, Stefan [11 ]
Juni, Peter [12 ,13 ]
Kunadian, Vijay [14 ]
Landi, Antonio [1 ,2 ]
Leonardi, Sergio [15 ,16 ]
Mehran, Roxana [17 ]
Montalescot, Gilles [18 ]
Navarese, Eliano Pio [19 ]
Niebauer, Josef [20 ]
Oliva, Angelo [21 ]
Piccolo, Raffaele [22 ]
Price, Susanna [23 ]
Storey, Robert F. [24 ]
Voeller, Heinz [25 ]
Vranckx, Pascal [26 ,27 ]
Windecker, Stephan [28 ]
Fox, Keith A. A. [29 ]
机构
[1] Cardioctr Ticino Inst, Div Cardiol, Ente Ospedaliero Cantonale, Via Tesserete 48, CH-6900 Lugano, Switzerland
[2] Univ Italian Switzerland, Dept Biomed Sci, Switzerland, Switzerland
[3] Dupuytren Univ Hosp, Dept Cardiol, 2Martin Luther King ave, F-87042 Limoges, France
[4] Dupuytren Univ Hosp, INSERM 1094 & IRD, 2Martin Luther King ave, F-87042 Limoges, France
[5] Univ Florida, Div Cardiol, Coll Med Jacksonville, 655 West 8th St, Jacksonville, FL 32209 USA
[6] Univ Oslo, Oslo Univ Hosp Ulleval, Dept Cardiol, Oslo, Norway
[7] Univ Oslo, Oslo Univ Hosp Ulleval, Inst Clin Med, Oslo, Norway
[8] Univ Catania, Div Cardiol, Azienda Ospedaliero Universitaria Policlin G Rodo, Via St Sofia 78, I-95123 Catania, Italy
[9] Univ Oslo, Inst Clin Med, Blindern, POB 1078, N-0316 Oslo, Norway
[10] Oslo Univ Hosp Ulleval, Dept Cardiol, Oslo, Norway
[11] Uppsala Univ, Uppsala Clin Res Ctr, Dept Med Sci, S-75185 Uppsala, Sweden
[12] Univ Toronto, Appl Hlth Res Ctr, Li Ka Shing Knowledge Inst, St Michaels Hosp,Dept Med, Toronto, ON, Canada
[13] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[14] Newcastle Tyne Hosp NHS Fdn Trust, Freeman Hosp, Cardiothorac Ctr, Newcastle Upon Tyne, Tyne & Wear, England
[15] Univ Pavia, Fdn IRCCS Policlin San Matteo, Pavia, Italy
[16] Fdn IRCCS Policlin San Matteo, Coronary Care Unit, Pavia, Italy
[17] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA
[18] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, ACTION Grp,INSERM,UMRS 1166,Inst Cardiol, Paris, France
[19] Nicolaus Copernicus Univ, Dept Cardiol & Internal Med, Bydgoszcz, Poland
[20] Paracelsus Med Univ Salzburg, Inst Sports Med Prevent & Rehabil, A-5020 Salzburg, Austria
[21] Humanity Univ, Dept Biomed Sci, I-20090 Milan, Italy
[22] Univ Naples Federico II, Dept Adv Biomed Sci, Div Cardiol, Naples, Italy
[23] Royal Brompton Hosp, Natl Heart & Lung Inst, Imperial Coll, London, England
[24] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Cardiovasc Res Unit, Sheffield, S Yorkshire, England
[25] Univ Potsdam, Fac Hlth Sci Brandenburg, Dept Rehabil Med, Potsdam, Germany
[26] Hartcentrum Hasselt, Dept Cardiol & Crit Care Med, Hasselt, Belgium
[27] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium
[28] Univ Bern, Dept Cardiol, Inselspital, Bern, Switzerland
[29] Univ Edinburgh, Ctr Cardiovasc Sci, Div Clin & Surg Sci, Edinburgh, Scotland
关键词
Antithrombotic treatment; Coronary artery disease; Percutaneous coronary intervention; Acute coronary syndrome; Chronic coronary syndrome; DUAL-ANTIPLATELET THERAPY; ACUTE MYOCARDIAL-INFARCTION; ELUTING STENT IMPLANTATION; VEIN-GRAFT PATENCY; CLOPIDOGREL PLATELET REACTIVITY; ARTERY-BYPASS-SURGERY; PRECISE-DAPT SCORE; LONG-TERM; OPEN-LABEL; DOUBLE-BLIND;
D O I
10.1093/ehjcvp/pvad032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple guidelines and consensus papers have addressed the role of antithrombotic strategies in patients with established coronary artery disease (CAD). Since evidence and terminology continue to evolve, the authors undertook a consensus initiative to guide clinicians to select the optimal antithrombotic regimen for each patient. The aim of this document is to provide an update for clinicians on best antithrombotic strategies in patients with established CAD, classifying each treatment option in relation to the number of antithrombotic drugs irrespective of whether the traditional mechanism of action is expected to mainly inhibit platelets or coagulation cascade. With the aim to reach comprehensiveness of available evidence, we systematically reviewed and performed meta-analyses by means of both direct and indirect comparisons to inform the present consensus document.
引用
收藏
页码:462 / 496
页数:35
相关论文
共 50 条
  • [21] ECONOMIC BURDEN OF DIABETIC PATIENTS WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR RISK FACTORS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Marcellusi, A.
    Sciattella, P.
    Bini, C.
    Rotundo, M.
    Aimaretti, G.
    Mennini, F. S.
    VALUE IN HEALTH, 2020, 23 : S509 - S509
  • [22] Antithrombotic Treatment Strategies
    Strauer, B. E.
    Schellong, S. M.
    INTERNIST, 2011, 52 (11): : 1275 - 1275
  • [23] Antithrombotic therapy and revascularisation strategies in people with diabetes and coronary artery disease
    Rocca, Bianca
    Rubboli, Andrea
    Zaccardi, Francesco
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (2_SUPPL) : 92 - 105
  • [24] Antithrombotic therapy in diabetic patients with coronary artery disease
    Lemesle, G.
    Bauters, A.
    Bauters, C.
    PANMINERVA MEDICA, 2015, 57 (02) : 87 - 99
  • [25] Antithrombotic Management of Elderly Patients With Coronary Artery Disease
    Capranzano, Piera
    Angiolillo, Dominick J.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2020, 14 (07) : 723 - 738
  • [26] ATHEROSCLEROTIC LESIONS IN PATIENTS WITH CORONARY HEART DISEASE
    STRONG, JP
    SOLBERG, LA
    RESTREPO, C
    CIRCULATION, 1966, 34 (4S3) : I31 - +
  • [27] Treatment Strategies in CKD Patients With Suspected Coronary Artery Disease
    Foley, Robert N.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 74 (04) : 438 - 440
  • [28] Wingspan experience in the treatment of symptomatic intracranial atherosclerotic disease after antithrombotic failure
    Samaniego, Edgar A.
    Tari-Capone, Francesca
    Linfante, Italo
    Silva, Christine F.
    Spilberg, Gabriela
    Gounis, Matthew
    Wakhloo, Ajay K.
    Dabus, Guilherme
    JOURNAL OF NEUROINTERVENTIONAL SURGERY, 2013, 5 (04) : 302 - 305
  • [29] Role of Rivaroxaban in the Antithrombotic Treatment of Patients with Coronary Heart Disease and Atrial Fibrillation after Percutaneous Coronary Intervention
    Fu, Chenyang
    Pan, Huichao
    Chen, Yu
    Liang, Shuo
    Xia, Bihua
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 84 : 71 - 75
  • [30] Established and Emerging Strategies in the Treatment of Chronic Kidney Disease
    Pena-Polanco, Julio E.
    Fried, Linda F.
    SEMINARS IN NEPHROLOGY, 2016, 36 (04) : 331 - 342